These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 18760592)

  • 21. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
    Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
    Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
    Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Levillain R; Tichet J; Launoy G
    Int J Cancer; 2009 Sep; 125(5):1127-33. PubMed ID: 19431212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early detection of colorectal cancer with faecal occult blood test screening.
    Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
    Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence.
    Grazzini G; Ciatto S; Cislaghi C; Castiglione G; Falcone M; Mantellini P; Zappa M;
    J Med Screen; 2008; 15(4):175-81. PubMed ID: 19106257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
    Brenner H; Tao S
    Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test.
    Oort FA; Terhaar Sive Droste JS; Van Der Hulst RW; Van Heukelem HA; Loffeld RJ; Wesdorp IC; Van Wanrooij RL; De Baaij L; Mutsaers ER; van der Reijt S; Coupe VM; Berkhof J; Bouman AA; Meijer GA; Mulder CJ
    Aliment Pharmacol Ther; 2010 Feb; 31(3):432-9. PubMed ID: 19878150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population.
    Morikawa T; Kato J; Yamaji Y; Wada R; Mitsushima T; Shiratori Y
    Gastroenterology; 2005 Aug; 129(2):422-8. PubMed ID: 16083699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial).
    Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P
    Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
    Haug U; Hundt S; Brenner H
    Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
    Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Levillain R; Tichet J; Launoy G
    Br J Cancer; 2009 Apr; 100(8):1230-5. PubMed ID: 19337253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colonoscopy results of a French regional FOBT-based colorectal cancer screening program with high compliance.
    Manfredi S; Piette C; Durand G; Plihon G; Mallard G; Bretagne JF
    Endoscopy; 2008 May; 40(5):422-7. PubMed ID: 18231963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.
    Federici A; Giorgi Rossi P; Borgia P; Bartolozzi F; Farchi S; Gausticchi G
    J Med Screen; 2005; 12(2):83-8. PubMed ID: 15949119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults.
    Graser A; Melzer A; Lindner E; Nagel D; Herrmann K; Stieber P; Schirra J; Mansmann U; Reiser MF; Göke B; Kolligs FT
    Gastroenterology; 2013 Apr; 144(4):743-750.e2. PubMed ID: 23415805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme.
    Faivre J; Dancourt V; Manfredi S; Denis B; Durand G; Gendre I; Bidan JM; Jard C; Levillain R; Jung S; Viguier J; Dorval E
    Dig Liver Dis; 2012 Aug; 44(8):700-4. PubMed ID: 22542582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.
    Greenberg PD; Bertario L; Gnauck R; Kronborg O; Hardcastle JD; Epstein MS; Sadowski D; Sudduth R; Zuckerman GR; Rockey DC
    Am J Gastroenterol; 2000 May; 95(5):1331-8. PubMed ID: 10811348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.